Technology
Health
Pharmaceutical

Jazz Pharmaceuticals

$139.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-0.15%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell JAZZ and other stocks, options, ETFs, and crypto commission-free!

About

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. Read More The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Dublin, Ireland.

Employees
1,360
Headquarters
Dublin, Dublin
Founded
2003
Market Cap
7.92B
Price-Earnings Ratio
17.35
Dividend Yield
0.00
Average Volume
600.90K
High Today
$140.83
Low Today
$138.50
Open Price
$138.70
Volume
114.42K
52 Week High
$184.00
52 Week Low
$113.52

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Europe (Non-UK)
Europe

News

Yahoo FinanceMay 8

Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

Jazz Pharmaceuticals plc JAZZ delivered adjusted earnings of $3.67 per share for the first quarter of 2019, which surpassed the Zacks Consensus Estimate of $3.16. Earnings rose 23% from the year-ago figure driven by higher sales and reduced share count.

13
The Motley FoolMay 8

Jazz Pharmaceuticals Hits All the Right Notes in Q1

The last time Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly results, there were some positives for investors. Revenue increased 17% year over year while earnings were up by 24%. Jazz announced its first-quarter results after the market closed on Tuesday. Did investors receive good news or bad news this time around? Here are the highlights from the company's Q1 update. By the numbers Jazz announced Q1 revenue of $508.2 million, a 14% increase from the $444.6 million reported in the same q...

25
The Motley FoolMay 8

Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript

Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2019 Earnings Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Jazz Pharmaceuticals plc first-quarter 2019 earnings conference call. [Operator instructions] As a reminder, this conference call is being recorded. I will now turn the call over to Kathee Littrell, head of investor relations at Jazz Pharmaceuticals. Kathee Littrell -- Head of Investor Relations Thank you, Joelle. And ...

1

Earnings

$2.77
$3.07
$3.37
$3.67
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$3.16 per share
Actual
$3.67 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.